Sign in Welcome! Log into your account your username your password Forgot your password? Get help Privacy Policy Password recovery Recover your password your email A password will be e-mailed to you. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities The I-TECH Randomized Clinical Trial Data analysesResource February 23, 2022 Share Telegram WhatsApp Facebook Twitter jamainternal_lim_2022_oi_220006_1644957301.61931 (1) (1).pdf(Shared)- Adobe Document Cloudhttps://acrobat.adobe.com/link/track?uri=urn%3Aaaid%3Ascds%3AUS%3A67e2255f-dc16-3934-80e3-b4fe3a818654#pageNum=1 Ludwig Van Search Latest articles COVID-19 vaccine-associated mortality in the Southern Hemisphere September 30, 2023 Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes September 12, 2023 The Planetary Theory of Solar Activity Variability: A Review September 9, 2023 ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA September 7, 2023 Previous articleThe Disinformation Campaign Against Ivermectin – JAMA’s “Diversion”Next articleNew JAMA paper shows Ivermectin blows the COVID vaccines out of the water Related articles COVID-19 vaccine-associated mortality in the Southern Hemisphere Resource September 30, 2023 Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes Resource September 12, 2023 The Planetary Theory of Solar Activity Variability: A Review Resource September 9, 2023 Leave a reply Cancel replyLog in to leave a comment
